The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the ...
Danish diabetes and obesity giant Novo Nordisk (NOV: N) today announced headline results from REDEFINE 2, a Phase III trial ...
With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.
Leading Russian drugmakers PSK Pharma and Promomed, which produce the analogues of Ozempic - a drug for the treatment of ...
Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...
Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...
The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
South Africa's competition watchdog launches a crucial investigation into pharmaceutical giants Novo Nordisk and Sanofi over their insulin pen market practices, amid growing concerns about ...
Apollo Global Management, Novo Nordisk A/S, BlackRock, Blackstone, and Prologis are the five Growth stocks to watch today, according to MarketBeat’s stock screener tool. Growth stocks are shares of ...